Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clearance of Driver Mutations after Transplantation for Myelofibrosis.
Gagelmann N, Quarder M, Badbaran A, Rathje K, Janson D, Lück C, Richter J, Marquard F, Oechsler S, Massoud R, Klyuchnikov E, Rudolph I, Schäfersküpper M, Niederwieser C, Heidenreich S, Berger C, Fehse B, Wolschke C, Ayuk F, Kröger N. Gagelmann N, et al. Among authors: wolschke c. N Engl J Med. 2025 Jan 9;392(2):150-160. doi: 10.1056/NEJMoa2408941. N Engl J Med. 2025. PMID: 39778169
Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML).
Schönrock M, Sonnemann P, Michalowski N, Heuser M, Thol F, Ayuk FA, Wolschke C, Klyuchnikov E, Bokemeyer C, Fiedler W, Cichutek S. Schönrock M, et al. Among authors: wolschke c. Cancers (Basel). 2024 Nov 19;16(22):3872. doi: 10.3390/cancers16223872. Cancers (Basel). 2024. PMID: 39594827 Free PMC article.
Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis.
Rathje K, Gagelmann N, Badbaran A, Langebrake C, Dadkhah A, Richter J, Massoud R, Schäfersküpper M, Marquard FE, Oechsler S, Klyuchnikov E, Rudolph I, Heidenreich S, Niederwieser C, Lueck C, Janson D, Wolschke C, Fehse B, Ayuk F, Kröger N. Rathje K, et al. Among authors: wolschke c. Am J Hematol. 2025 Feb;100(2):200-209. doi: 10.1002/ajh.27529. Epub 2024 Nov 16. Am J Hematol. 2025. PMID: 39548811 Free PMC article.
Sequential Conditioning With FLAMSA Does Not Improve Outcomes of Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia Patients.
Massoud R, Klyuchnikov E, Steiner N, Zeck G, Heidenreich S, Langebrake C, Niederwieser C, Rathje K, Gagelmann N, Janson D, Wolschke C, Ayuk F, Kröger N. Massoud R, et al. Among authors: wolschke c. Transplant Cell Ther. 2024 Oct 16:S2666-6367(24)00696-1. doi: 10.1016/j.jtct.2024.10.003. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39419178 Free article.
Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission.
Steiner N, Massoud R, Richter J, Perekhrestenko T, Gagelmann N, Niederwieser C, Rathje K, Lastovytska I, Schäfersküpper M, Heidenreich S, Rudolph I, Zeck G, Janson D, Wolschke C, Ayuk FA, Klyuchnikov E, Kröger N. Steiner N, et al. Among authors: wolschke c. Eur J Haematol. 2025 Jan;114(1):79-88. doi: 10.1111/ejh.14305. Epub 2024 Sep 19. Eur J Haematol. 2025. PMID: 39300830 Free PMC article.
Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation.
Steiner N, Massoud R, Klyuchnikov E, Gagelmann N, Richter J, Niederwieser C, Rathje K, Urbanowicz T, Kunte A, Engelmann J, Ihne C, Lastovytska I, Lindhauer C, Marquard F, Reichard M, Ryzhkova A, Sabauri R, Schäfersküpper M, Seyedi N, Kalogeropoulos G, Heidenreich S, Rudolph I, Zeck G, Janson D, Wolschke C, Ayuk F, Kröger N. Steiner N, et al. Among authors: wolschke c. Bone Marrow Transplant. 2024 Sep;59(9):1265-1274. doi: 10.1038/s41409-024-02328-w. Epub 2024 Jun 14. Bone Marrow Transplant. 2024. PMID: 38877098 Free PMC article.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Free PMC article. Clinical Trial.
Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation.
Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, Massoud R, Rathje K, Richter J, Schäfersküpper M, Niederwieser C, Kunte A, Heidenreich S, Ayuk F, Kröger N. Oechsler S, et al. Among authors: wolschke c. Bone Marrow Transplant. 2024 Apr;59(4):550-557. doi: 10.1038/s41409-024-02220-7. Epub 2024 Feb 6. Bone Marrow Transplant. 2024. PMID: 38321269 Free PMC article.
Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR.
Klyuchnikov E, Badbaran A, Massoud R, Freiberger P, Wolschke C, Ayuk F, Fehse B, Bacher U, Kröger N. Klyuchnikov E, et al. Among authors: wolschke c. Leukemia. 2024 Feb;38(2):386-388. doi: 10.1038/s41375-024-02148-3. Epub 2024 Jan 23. Leukemia. 2024. PMID: 38263432 No abstract available.
126 results